MED · Insider Trading
Medifast, Inc.
Every open-market purchase and sale reported by MED officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | Parsa Kiai | Director | Buy | — | — |
| 2026-08-26 | Parsa Kiai | Director | Buy | — | — |
| 2026-08-21 | Parsa Kiai | Director | Buy | — | — |
| 2026-05-28 | Jeffrey Matthew Rose | Director | A | — | — |
| 2026-05-28 | Andrea B Thomas | Director | A | — | — |
| 2026-05-28 | Ming Xian | Director | A | — | — |
| 2026-05-28 | Elizabeth A. Geary | Director | A | — | — |
| 2026-05-28 | SCOTT SCHLACKMAN | Director | A | — | — |
| 2026-05-28 | Parsa Kiai | Director | A | — | — |
| 2026-05-12 | SCOTT SCHLACKMAN | Director | Buy | — | — |
| 2026-03-27 | Jonathan Barrett MacKenzie | VP, Finance & CAO | MIXED | — | — |
| 2026-03-27 | James P. Maloney | Chief Financial Officer | MIXED | — | — |
| 2026-03-27 | Daniel R Chard | Chairman & CEO | MIXED | — | — |
| 2025-06-26 | SCOTT SCHLACKMAN | Director | A | — | — |
| 2025-06-26 | Andrea B Thomas | Director | A | — | — |
| 2025-06-26 | Elizabeth A. Geary | Director | A | — | — |
| 2025-06-26 | Michael A. Hoer | Director | A | — | — |
| 2025-06-26 | Ming Xian | Director | A | — | — |
| 2025-06-26 | JEFFREY J BROWN | Director | A | — | — |
| 2025-06-17 | Daniel R Chard | Chairman & CEO | Buy | — | — |
| 2025-03-27 | James P. Maloney | Chief Financial Officer | A | — | — |
| 2025-03-27 | Jonathan Barrett MacKenzie | VP, Finance & CAO | A | — | — |
| 2025-03-27 | Daniel R Chard | Chairman & CEO | A | — | — |
| 2025-03-18 | James P. Maloney | Chief Financial Officer | F | — | — |
| 2025-03-18 | Jonathan Barrett MacKenzie | VP, Finance & CAO | F | — | — |
| 2025-03-18 | Daniel R Chard | Chairman & CEO | F | — | — |
| 2024-09-17 | Jonathan Barrett MacKenzie | VP, Finance & CAO | F | — | — |
| 2024-06-24 | Ming Xian | Director | A | — | — |
| 2024-06-24 | Elizabeth A. Geary | Director | A | — | — |
| 2024-06-24 | Andrea B Thomas | Director | A | — | — |
| 2024-06-24 | JEFFREY J BROWN | Director | A | — | — |
| 2024-06-24 | Michael A. Hoer | Director | A | — | — |
| 2024-06-24 | SCOTT SCHLACKMAN | Director | A | — | — |
| 2024-03-19 | Jonathan Barrett MacKenzie | VP, Finance & CAO | F | — | — |
| 2024-03-19 | James P. Maloney | Chief Financial Officer | F | — | — |
| 2024-03-19 | Daniel R Chard | Chairman & CEO | F | — | — |
| 2024-03-15 | James P. Maloney | Chief Financial Officer | A | — | — |
| 2024-03-15 | Jonathan Barrett MacKenzie | VP, Finance & CAO | A | — | — |
| 2024-03-15 | Daniel R Chard | Chairman & CEO | A | — | — |
| 2024-03-12 | SCOTT SCHLACKMAN | Director | MIXED | — | — |
| 2024-02-16 | Daniel R Chard | Chairman & CEO | MIXED | — | — |
| 2024-02-16 | James P. Maloney | Chief Financial Officer | MIXED | — | — |
| 2023-11-09 | JEFFREY J BROWN | Director | Buy | — | — |
| 2023-11-09 | Andrea B Thomas | Director | Buy | — | — |
| 2023-11-09 | Ming Xian | Director | Buy | — | — |
| 2023-11-09 | SCOTT SCHLACKMAN | Director | Buy | — | — |
| 2023-11-09 | Michael A. Hoer | Director | Buy | — | — |
| 2023-10-30 | CONSTANCE J. HALLQUIST | — | Sell | — | — |
| 2023-09-15 | Jonathan Barrett MacKenzie | VP, Finance & CAO | F | — | — |
| 2023-08-16 | JEFFREY J BROWN | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,251,988 | — |
| — | 10%+ Owner | 1,194,891 | — |
| — | Director | 719,172 | — |
| — | Exec. Chairman of the Board | 579,521 | — |
| — | Executive Vice President | 425,183 | — |
| — | Chief Executive Officer | 340,012 | — |
| — | President & COO | 333,926 | — |
| — | Chairman & CEO | 318,869 | — |
| — | Director | 280,802 | — |
| — | Chief Financial Officer | 91,484 | — |
| — | — | 62,081 | — |
| — | Chief Financial Officer | 47,214 | — |
| — | Director | 45,342 | — |
| — | Director | 42,810 | — |
| — | Director | 42,228 | — |
| — | Chief Financial Officer | 40,899 | — |
| — | Director | 35,697 | — |
| — | Director | 31,225 | — |
| — | Director | 27,689 | — |
| — | Director | 26,139 | — |
| — | Director | 24,785 | — |
| — | Director | 21,700 | — |
| — | Executive VP & General Counsel | 21,697 | — |
| — | Executive Vice President | 20,116 | — |
| — | Director | 18,419 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MED quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.